At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Placebo 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Parallel Group Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP).
In Brief
A Phase 2 clinical trial evaluating Placebo and Avatrombopag tablets for Chronic Idiopathic Thrombocytopenic Purpura and Purpura, Thrombocytopenic, Idiopathic. Completed, enrolled 64 participants across 25 sites.
Detailed Summary
The purpose of this study is to determine the efficacy, safety and tolerability, of AKR-501 (avatrombopag) tablets, as compared to placebo, in the treatment of participants with chronic Idiopathic Thrombocytopenic Purpura (ITP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedFeb 2007
Primary CompletionJan 2009
Study CompletionJun 2009
TodayJul 2026
First PostedFeb 28, 2007
Enrollment StartFeb 1, 2007
Primary CompletionJan 1, 2009
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.3 years ago
Interventions
Placebodrug
Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
Avatrombopag tabletsdrug
Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.